Preclinical Evaluation of a Thymidine Phosphorylase Imaging Probe, [I]IIMU, for Translational Research by unknown
Chapter 9
Preclinical Evaluation of a Thymidine
Phosphorylase Imaging Probe, [123I]IIMU,
for Translational Research
Ken-ichi Nishijima, Songji Zhao, Fei Feng, Yoichi Shimizu,
Hiromichi Akizawa, Kazue Ohkura, Nagara Tamaki, and Yuji Kuge
Abstract The expression of thymidine phosphorylase (TP) is closely associated
with angiogenesis, tumor invasiveness, and activation of antitumor agents. We
developed a radiolabeled uracil derivative, I-123-labeled 5-iodo-6-[(2-iminoimida-
zolidinyl)methyl]uracil ([123I]IIMU), as a novel SPECT probe for TP. A clinical
study to verify the safety of [123I]IIMU injection was approved by the Institutional
Review Board of Hokkaido University Hospital for Clinical Research, and first-in-
human (FIH) clinical studies of healthy adults were started.
Here, we will introduce our research, including the synthesis of [123I]IIMU and
its efficacy and safety evaluation, toward its FIH clinical study.
Radiosynthesis of [123I]IIMU: [123I]IIMU synthesis was achieved by
radioiodination of the precursor, 6-(2-iminoimidazolidinyl)methyluracil at the
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C-5 position with N-chlorosuccinimide/[123I]NaI. After purification by HPLC,
[123I]IIMU was obtained in high radiochemical yields.
In vitro and in vivo studies: The in vitro and in vivo uptake of [125I]IIMU by the
A431 tumor was attributable to the binding of the radiotracer to its target
enzyme, i.e., TP. SPECT/CT imaging with [123I]IIMU clearly visualized the
A431 tumor 3 h after the injection of n.c.a. [123I]IIMU.
Safety assessment: The human radiation absorbed dose was estimated as 17 μSv/
MBq on the basis of the biodistribution data of [I]IIMU in normal mice. The no
observed adverse effect level (NOAEL) for intravenous administration of
non-radiolabeled IIMU to mice was higher than 1.8 mg/kg. The bacterial reverse
mutation assay showed negative results.
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9.1 Introduction
Thymidine phosphorylase (TP) catalyzes the reversible phosphorolysis of thymi-
dine to thymine and 2-deoxyribose-1-phosphate. The expression of TP is highly
associated with angiogenesis, infiltration, and metastasis of tumors. The activity
and expression level of TP in many tumors are higher than those in the adjacent
nonneoplastic tissues [1].
We developed a radiolabeled uracil derivative, I-123-labeled 5-iodo-6-
[(2-iminoimidazolidinyl)methyl]uracil ([123I]IIMU, Fig. 9.1), as a novel SPECT
probe for TP.A clinical study to verify the safety of [123I]IIMU injectionwas approved
by the Institutional Review Board of Hokkaido University Hospital for Clinical
Research, and first-in-human (FIH) clinical studies on healthy adults were started.
Here, we will introduce our research, including the synthesis of [123I]IIMU [2, 3]
and its efficacy [4–6] and safety evaluation, toward its FIH clinical study.
9.2 Radiosynthesis of [123I]IIMU [2]
[123I]IIMU was synthesized according to a method previously reported [3]. Briefly,
dry acetone containing N-chlorosuccinimide/AcOH was added to [123I]NaI
(370 MBq) in a reaction vial, and the mixture was allowed to stand for 10 min at
room temperature. Acetone was then removed completely under a stream of N2. A
Fig. 9.1 Structure of [123I]
IIMU hydrochloride
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solution of 6-[(2-iminoimidazolidinyl)methyl]uracil (HIMU-TFA) in aqueous ace-
tonitrile (CH3CN/H2O¼ 2:1) was added to the residue, and the capped vial was
heated for 35 min at 50 C. After removal of the solvent, the crude product was
converted to [123I]IIMU-HCl and purified simultaneously by reversed-phase HPLC
using a solvent system containing HCl. The radioactive fraction was sterilized
through a 0.22 μm membrane filter. The radiochemical purity of [123I]IIMU was
determined with HPLC. Residual organic solvents were determined with
GC. Sterility tests and bacterial endotoxin tests were also performed.
[123I]IIMU for intravenous injection was prepared in 2.5 h with a yield of
205 24 MBq (n¼ 3). The radiochemical purity of [123I]IIMU was found to be
more than 99 % (Table 9.1). The results of the quality control tests are summarized
in Table 9.2. Acetone was not detected in the solution. The ethanol concentration
was 104 111 ppm. Sterility tests and bacterial endotoxin tests showed negative
results (Table 9.2). We successfully prepared [123I]IIMU for intravenous injection
with high purity. Results of quality control tests demonstrate that the [123I]IIMU
preparation is suitable for clinical studies.
9.3 In Vitro Study: Uptake of [125I]IIMU in Cultured A431
and AZ521 Cells [4]
Immunoblotting for the detection of TP demonstrated high enzyme expression in
A431 human epithelial carcinoma cells and very low expression in AZ521 human
gastric cancer cells. A431 or AZ521 cells in 24-well plates were incubated at 37 C
in 1 mL of PBS() containing 37 kBq of [125I]IIMU for 10, 30, 60, or 120 min. The
Table 9.1 Production data for three consecutive syntheses of [123I]IIMU
Parameter
Run number
1 2 3 Mean SD
Yield at the end of preparation (MBq) 232 189 193 205 24
Radiochemical yield (%) 62 51 52 55 6
Radiochemical purity (%) >99 >99 >99 >99
Table 9.2 Results of quality control tests for three consecutive syntheses of [123I]IIMU
Parameter
Run number
1 2 3 Mean SD
pH 7 7 7 7 0
Residual organic solvent (ppm) EtOH 46.8 232.6 33.4 104 111
MeCN 2.2 ND 2.3 1.5 1.3
Acetone ND ND ND –
Tests for bacterial endotoxins Negative Negative Negative –
Sterility test Negative Negative Negative –
ND: Not detected (<1.0)
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incubation solution was removed, and cells were washed and solubilized in 0.7 mL
of 0.2 M NaOH. The radioactivity and protein content of the cell lysate were
evaluated. When the radiotracer was incubated with A431 cells, the uptake level
of the radiotracer increased with an increase in the incubation time, with 5.3 %
dose/mg protein at 2 h of incubation. In the case of AZ521 cells, uptake of
radioactivity was extremely low, 0.68 % dose/mg protein at most, regardless of
incubation time. To confirm whether the observed uptake is due to the binding of
the tracer to TP, similar experiments with A431 tumors were conducted in the
presence of various concentrations of nonlabeled IIMU. The uptake level of [125I]
IIMU in A431 cells was reduced depending on the concentration of
nonlabeled IIMU.
9.4 In Vivo Study: Biodistribution of [125I]IIMU in A431
and AZ521 Tumor-Bearing Nude Mice [4]
The entire experimental protocol was approved by the Laboratory Animal Care and
Use Committee of Hokkaido University. A saline solution of [125I]IIMU (37 kBq,
0.1 mL) was injected into the tail vein of A431 or AZ521 tumor-bearing female
Balb/cAJc1-nu/nu mice (8 weeks old; about 20 g ). At 0.5, 1, 3, and 24 h after
administration, animals were euthanized and the organs of interest and blood were
collected. Radioactivity levels in the blood and muscle were similar in A431 and
AZ521 tumor-bearing mice. However, tumor accumulation levels were markedly
different between the two; the A431 tumor with high TP expression showed high
accumulation, while AZ521 tumor with low TP expression showed low accumula-
tion. To hamper the binding of the tracer to TP, an excess amount of
non-radiolabeled IIMU was administered to A431 tumor-bearing mice and the
biodistribution was evaluated at 0.5 h postinjection. The radioactivity in A431
tumor was reduced by co-injection of nonlabeled IIMU.
The in vitro and in vivo uptake of [125I]IIMU by the A431 tumor was attributable
to the binding of the radiotracer to its target enzyme, i.e., TP.
9.5 SPECT/CT Imaging Study [2]
Small-animal SPECT imaging studies were performed in mice bearing A431
xenografts after intravenous injection of non-carrier-added (n.c.a.) [123I]IIMU or
[123I]IIMU with an excessively large amount of nonlabeled IIMU (n¼ 3 per group)
by using a small-animal PET/SPECT/CT. SPECT/CT imaging with [123I]IIMU
clearly visualized A431 tumor 3 h after the injection of n.c.a. [123I]IIMU
(Fig. 9.2a). The accumulation of [123I]IIMU in the tumor and liver was inhibited
by the co-injection of non-radiolabeled IIMU (Fig. 9.2b).
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9.6 Safety Assessment
To realize the application of [123I]IIMU to clinical studies, we performed safety
assessment of [123I]IIMU. Evaluation of radiation absorbed dose is important for
the safety assessment of radiopharmaceuticals. The human radiation absorbed dose
was estimated as 17 μSv/MBq on the basis of the biodistribution data of [125I]IIMU
in normal mice. The highest radiation dose was of the urinary bladder (130 μGy/
MBq), followed by the liver (75.1 μGy/MBq), thyroid (47.3 μGy/MBq), and
gallbladder (20.4 μGy/MBq). The human radiation absorbed dose of [123I]IIMU
was considered to be within the allowable range and is equal to or less than the
human radiation absorbed dose of [18F]FDG (21 μSv/MBq; ICPR 60).
Also, based on the “guidance for conducting microdose clinical trials,” we
performed an extended single-dose toxicity study and the bacterial reverse mutation
assay (Ames test). In the extended single-dose toxicity study, SD rats were given a
single intravenous dose (0, 0.18, and 1.8 mg/kg) on Day 1, followed by observations
until termination on Day 14. There were no deaths or in-life clinical signs and there
were no microscopic effects. The no observed adverse effect level (NOAEL) for
intravenous administration of nonlabeled IIMU to mice was greater than 1.8 mg/kg.
The bacterial reverse mutation assay showed negative results.
Fig. 9.2 SPECT/CT images of mice bearing A431 tumors. Mice were injected with 25 MBq of
n.c.a. [123I]IIMU (a) or [123I]IIMU with non-radiolabeled IIMU (b)
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9.7 Conclusions
Our findings indicate that [123I]IIMU should be developed as a diagnostic agent for
imaging TP-expressing tumors. It was shown that [123I]IIMU injection can be
safely administered in preclinical studies. Examinations using [123I]IIMU for injec-
tion are expected to provide useful information that is difficult to obtain by other
conventional methods, such as estimation/determination of therapeutic effects of
anticancer drugs, decision-making for a treatment plan, prognostic prediction,
understanding of disease stages, and malignancy assessment.
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